medtourism.guideIndependent check of what clinics publish

H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc.

United StatesOfficial site: eforms.moffitt.org ↗Source pages: eforms.moffitt.org

H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. (United States) publishes no comparable price on its own website for cancer treatment. We found none of the four terms on its site (guarantee, redo policy, aftercare at home, named doctor). Checked 14 Nov 2026.

Facts reported from this provider's own pages, with the date we checked.

Travelling from

Figures are converted to Canadian dollars for comparison only. The clinic charges in the currency it publishes; your bank's rate and card fees will differ.

Published positions

Status of each term on the provider's own page: Published Partly Not stated By enquiry

Cancer treatment in the United States

Prices with one fact not stated shown as the clinic publishes them; kept out of the medians, «from» prices and cheapest-clinic lines until the clinic states the missing fact

Procedure and scopePublished price≈ CADGuaranteeRedoNamed doctorAftercareChecked
AXICABTAGENE CILOLEUCEL (YESCARTA)product entry
686,125discountedCurrency not stated
— Not stated Not stated Not stated Not stated
14 Nov 2026source ↗
BREXUCABTAGENE AUTOLEUCEL UP TO 200 MILLION AUTOLOGOUS ANTI CD19 CAR POSITIVE VIABLE T CELLS IV SUSPENSION TECARTUS LYMPHOMAproduct entry
629,475discountedCurrency not stated
— Not stated Not stated Not stated Not stated
14 Nov 2026source ↗
IDECABTAGENE VICLEUCEL (ABECMA), UP TO 460 MILLION AUTOLOGOUS B-CELL MATURATION ANTIGEN (BCMA) DIRECTED CAR-POSITIVE T CELLS, PER THERAPEUTIC DOSEtherapeutic dose
680,202discountedCurrency not stated
— Not stated Not stated Not stated Not stated
14 Nov 2026source ↗

About this clinic

Details

Cancer treatment in the United States

checked 6 days ago3 positions
AXICABTAGENE CILOLEUCEL (YESCARTA)
product entry
686,125 — currency not stated
discounted
BREXUCABTAGENE AUTOLEUCEL UP TO 200 MILLION AUTOLOGOUS ANTI CD19 CAR POSITIVE VIABLE T CELLS IV SUSPENSION TECARTUS LYMPHOMA
product entry
629,475 — currency not stated
discounted
IDECABTAGENE VICLEUCEL (ABECMA), UP TO 460 MILLION AUTOLOGOUS B-CELL MATURATION ANTIGEN (BCMA) DIRECTED CAR-POSITIVE T CELLS, PER THERAPEUTIC DOSE
therapeutic dose
680,202 — currency not stated
discounted

Included, as published

  • AXICABTAGENE CILOLEUCEL (YESCARTA): not stated
  • BREXUCABTAGENE AUTOLEUCEL UP TO 200 MILLION AUTOLOGOUS ANTI CD19 CAR POSITIVE VIABLE T CELLS IV SUSPENSION TECARTUS LYMPHOMA: not stated
  • IDECABTAGENE VICLEUCEL (ABECMA), UP TO 460 MILLION AUTOLOGOUS B-CELL MATURATION ANTIGEN (BCMA) DIRECTED CAR-POSITIVE T CELLS, PER THERAPEUTIC DOSE: not stated

Not included, as published

  • Not stated on the page
Written guarantee
Not stated
Revision policy
Not stated
Named treating doctor
Not stated
After you return home
Not stated
Source: the provider's own page · observed 14 Nov 2026eforms.moffitt.org ↗

Appears on

Is this your clinic? Correct or add to what we show — free, with your name and the date.

Is this your clinic? A free badge for your website that links to this page.